Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

al compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and development activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; inability or delay in establishing sales infrastructure to support potential commercialization; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates; and our ability to raise additional capital as needed. For further information regarding these and other risks r
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
(Date:1/14/2014)... 14, 2014 Kerr Corporation, a leading manufacturer ... additional how-to information about dual arch impressions on its dental ... Arch Impressions,” the blog entry serves up a list of ... a step-by-step demonstration by Dr. David Little as he crafts ...
(Date:1/14/2014)... Research Triangle Park, NC (PRWEB) January 14, 2014 ... diagnostic company focusing on ultra-sensitive POC diagnostic platforms and novel ... on their first round of financing netting a total of ... first outside equity capital in the company. This group of ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2BioMedomics, Inc. Closes $690K Round of Financing 2
... ancient and proud history of interstate sports rivalries (especially ... this past New Years Day, the rivalry generates nasty ... marijuana have in common? They both get smoked in ... another interstate rivalry. This one is of keen interest ...
... -RedPrairie announced Wednesday it will support American Musical ... of supply chain execution solutions. AMS , ... a customer distribution network next year and develop ... and enterprise vision products. , ,AMS was ...
... a calm before the storm. The plans are set, the ... spent in quiet preparations by a group of outstanding companies ... producer of the event, I'm bound by the rules that ... at the conference on February 15. And as DEMO has ...
Cached Biology Technology:For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 2For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 3For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 4The Calm Before the Storm: Hot New Firms and Technologies 2The Calm Before the Storm: Hot New Firms and Technologies 3
(Date:4/23/2014)... read quickly. It involves visual searching for clues ... sentences. Similarly to humans, biological systems are sometimes ... Genes that need to be read quickly are ... the easier it will be to read them ... (IGC, Portugal) and Centre for Molecular and Structural ...
(Date:4/22/2014)... team of Yale researchers will lead a five-year, $3 ... rain events is affecting the transport of dissolved organic ... they say could alter the chemical composition and water ... With funding from the National Science Foundation,s MacroSystems Biology ... across the watershed, which begins in Canada and runs ...
(Date:4/22/2014)... Consortium Ltd.,s nanotechnology expert will present a poster ... at the 7th International Nanotoxicology Congress to ... , Dr. Monita Sharma will outline a strategy consistent ... of Sciences, " Toxicity Testing in the 21st Century: ... of non-animal methods involving human cells and cell lines ...
Breaking Biology News(10 mins):Cell division speed influences gene architecture 2Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3
... SPRING HARBOR, N.Y. A new book, ... CSHL,s mix of historic and modern buildings and the striking ... preservationist and tree enthusiast Elizabeth L. Watson, who, together with ... in various homes on the picturesque grounds of CSHL for ...
... ARGONNE, Ill. (June 9, 2008) The Institute for Genomics ... Department of Energy,s (DOE) Argonne National Laboratory and the University ... enhanced ability to sequence genomes more quickly and broadly. ... by searching only on the fairway, but not the rough," ...
... HARBOR, N.Y. The appointment of James Watson ... set off an explosive development of research at Cold ... wisely teams of investigators with diverse scientific interests. ... by the scientists involved tell the stories of research ...
Cached Biology News:Argonne-University of Chicago joint venture bolsters genomic sequencing capabilities 2Watson-inspired innovation in research at Cold Spring Harbor Laboratory 2
... Yeast ProtoArray high-density functional protein microarray is ... elucidation of proteinprotein interactions on a proteome ... cerevisiae open reading frames (ORFs) expressed as ... on a 1 inch x 3 inch ...
... is a compact, versatile system that simultaneously ... or 24-well microplates into a solid filter ... scintillation and gamma counter. The FilterMate is ... applications such as cell proliferation, receptor binding, ...
... Corning single use spatulas have been designed ... They are for those interested in eliminating ... spatulas. Each spatula is individually packaged, RNase/DNase ... number is a new product number, created ...
... Competitor Assay Kits are ideal for ... binding compounds using fluorescence polarization (FP) ... of glutathione transferase to the ligand ... [PR-LBD(GST)] and a proprietary, fluorescently-tagged progesterone ...
Biology Products: